SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome
Publication Type:Journal Article
Source:Cancer Biology and Therapy, Volume 10, Number 8, p.796-810 (2010)
Keywords:adult, aged, Amino acids, article, Biological, biological marker, Blotting, Carbon Isotopes, Carcinoma, Cell Line, Chromatography, controlled study, disulfide, drug binding, drug efficacy, ecalectin, Electrophoresis, Esophageal Neoplasms, esophageal squamous cell carcinoma, galactoside, gene overexpression, guanine nucleotide dissociation inhibitor, human, human cell, Humans, immunoblotting, immunohistochemistry, interstitial collagenase, Isotope Labeling, lectin, liquid, mass spectrometry, middle aged, Nitrogen Isotopes, Polyacrylamide Gel, polyacrylamide gel electrophoresis, protein analysis, protein disulfide isomerase, protein expression, protein secretion, proteome, proteomics, quantitative analysis, Squamous Cell, stable isotope labeling by amino acid in cell culture, tandem mass spectrometry, Tissue Array Analysis, tissue microarray, transferrin receptor, transforming growth factor beta, Tumor, tumor marker, Tumor Markers, upregulation, Western
The identification of secreted proteins that are differentially expressed between non-neoplastic and esophageal squamous cell carcinoma (ESCC) cells can provide potential biomarkers of ESCC. We used a SILAC-based quantitative proteomic approach to compare the secretome of ESCC cells with that of non-neoplastic esophageal squamous epithelial cells. Proteins were resolved by SDS-PAGE and tandem mass spectrometry analysis (LC-MS/MS) of in-gel trypsin-digested peptides was carried out on a high-accuracy qTOF mass spectrometer. In total, we identified 441 proteins in the combined secretomes, including 120 proteins with ≥2-fold upregulation in the ESCC secretome vs. that of non-neoplastic esophageal squamous epithelial cells. In this study, several potential protein biomarkers previously known to be increased in ESCC including matrix metalloproteinase 1, transferrin receptor and transforming growth factor beta-induced 68 kDa were identified as overexpressed in the ESCC-derived secretome. In addition, we identified several novel proteins that have not been previously reported to be associated with ESCC. Among the novel candidate proteins identified, protein disulfide isomerase family a member 3 (PDIA3), GDP dissociation inhibitor 2 (GDI2) and lectin galactoside binding soluble 3 binding protein (LGALS3BP) were further validated by immunoblot analysis and immunohistochemical labeling using tissue microarrays. This tissue microarray analysis showed overexpression of protein disulfide isomerase family a member 3, GDP dissociation inhibitor 2 and lectin galactoside binding soluble 3 binding protein in 93%, 93% and 87% of 137 ESCC cases, respectively. Hence, we conclude that these potential biomarkers are excellent candidates for further evaluation to test their role and efficacy in the early detection of ESCC. © 2010 Landes Bioscience.
cited By (since 1996)17
Cite this Research Publication
Related Research Publications
- Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma
- Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome
- Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma
- Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics
- Synovial fluid proteome in rheumatoid arthritis.